Different regulation of *PARP1*, *PARP2*, *PARP3* and *TRPM2* genes expression in acute myeloid leukemia cells

Paulina Gil-Kulik (✉ pgil.poczt@vp.pl)

Uniwersytet Medyczny w Lublinie <https://orcid.org/0000-0003-3119-981X>

Ewa Dudzińska

Uniwersytet Medyczny w Lublinie

Elżbieta Radzikowska-Büchner

Department of Plastic Surgery Saint Elizabeth Hospital

Joanna Wawer

Uniwersytet Medyczny w Lublinie

Mariusz Jojczuk

Uniwersytet Medyczny w Lublinie

Adam Nogalski

Uniwersytet Medyczny w Lublinie

Genowefa Anna Wawer

Uniwersytet Medyczny w Lublinie

Marcin Feldo

Uniwersytet Medyczny w Lublinie

Wojciech Kocki

Politechnika Lubelska

Maria Cioch

Uniwersytet Medyczny w Lublinie

Anna Bogucka-Kocka

Uniwersytet Medyczny w Lublinie

Mansur Rahnema

Uniwersytet Medyczny w Lublinie

Janusz Kocki

Uniwersytet Medyczny w Lublinie

Research article

Keywords: PARP1, PARP2, PARP3, TRPM2 gene expression, AML, hematopoietic stem cells

Posted Date: May 4th, 2020

DOI: <https://doi.org/10.21203/rs.2.19004/v3>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at BMC Cancer on May 18th, 2020. See the published version at <https://doi.org/10.1186/s12885-020-06903-4>.

Abstract

Background: Acute myeloid leukemia (AML) is a heterogenic lethal disorder characterized by the accumulation of abnormal myeloid progenitor cells in the bone marrow which results in hematopoietic failure. Despite various efforts in detection and treatment, many patients with AML die of this cancer. That is why it is important to develop novel therapeutic options, employing strategic target genes involved in apoptosis and tumor progression.

Methods: The aim of the study was to evaluate *PARP1*, *PARP2*, *PARP3*, and *TRPM2* gene expression at mRNA level using qPCR method in the cells of hematopoietic system of the bone marrow in patients with acute myeloid leukemia, bone marrow collected from healthy patients, peripheral blood of healthy individuals, and hematopoietic stem cells from the peripheral blood after mobilization.

Results: The results found that the bone marrow cells of the patients with acute myeloid leukemia (AML) show overexpression of *PARP1* and *PARP2* genes and decreased *TRPM2* gene expression. In the hematopoietic stem cells derived from the normal marrow and peripheral blood after mobilization, the opposite situation was observed, i.e. *TRPM2* gene showed increased expression while *PARP1* and *PARP2* gene expression was reduced. We observed positive correlations between *PARP1*, *PARP2*, *PARP3*, and *TRPM2* genes expression in the group of mature mononuclear cells derived from the peripheral blood and in the group of bone marrow-derived cells. In AML cells significant correlations were not observed between the expression of the examined genes. In addition, we observed that the reduced expression of *TRPM2* and overexpression of *PARP1* are associated with a shorter overall survival of patients, indicating the prognostic significance of these genes expression in AML.

Conclusions: Our research suggests that in physiological conditions in the cells of the hematopoietic system there is mutual positive regulation of *PARP1*, *PARP2*, *PARP3*, and *TRPM2* genes expression. *PARP1*, *PARP2*, and *TRPM2* genes at mRNA level deregulate in acute myeloid leukemia cells.

Background

Acute myeloid leukemia (AML) is a heterogenic lethal disorder characterized by the accumulation of abnormal myeloid progenitor cells in the bone marrow which results in hematopoietic failure. A major contributing factor to the high mortality rate associated with acute myeloid leukemia is developing resistance to chemotherapy [1]. Despite various efforts in detection and treatment, many patients with AML die of this cancer [1]. Therefore it is important to develop novel therapeutic options, employing strategic target genes involved in apoptosis and tumor progression [2].

Polymerases poly (ADP-ribose) PARP is a family of seventeen proteins that react with poly or mono ADP-ribosylation, and are involved in numerous cellular processes such as DNA repair, cell death, transcription, translation, cell proliferation, or cell response to oxidative stress. PARPs have the ability to modulate the transcriptional functions of both tumor suppressors and oncogenes which affects the ability of PARP to elicit contextual proton and antineoplastic effects [3].

PARP1, PARP2, and PARP3 are involved in the repair of DNA damage. Hence, it is recommended to use PARP inhibitors (PARPi) in the treatment of tumors, in particular those that do not have the ability to recombine (homologous recombination - HR) due to the mutations causing loss of BRCA1 or BRCA2 function. This phenomenon is referred to as synthetic lethality [4, 5, 6].

In many types of tumors, elevated *PARP1* mRNA is associated with poor prognosis and thus a shorter survival time. Increased expression of *PARP1* has been demonstrated in various types of tumors, including breast cancer, soft tissue sarcomas, endometrial adenocarcinoma, gliomas, colorectal cancer, myelodysplastic syndrome, neuroma, malignant lymphoma, testicular cancer, ovarian cancer [7, 8, 9, 10, 11]. *PARP1* was also found in acute myeloid leukemia and is suggested to be an independent prognostic factor in AML [9, 10].

Hyperactivation of PARP pathway observed in tumors can be used to selectively kill tumor cells. PARPi treatment was shown to be effective in monotherapy and in combination therapies mainly in gynecological cancers, and researchers also suspect potential of PARP inhibitors involvement in acute myeloid leukemia [9, 12, 13].

Recent studies show that PARP may also be involved in the epigenetic regulation maintaining stem cell pluripotency, and their expression is probably necessary for the proper differentiation of stem cells, including hematopoietic stem cells. Some authors even suggest that PARP can be used to reprogram somatic stem cells towards induced pluripotent stem cell (iPSC) [14, 15, 16, 17, 18].

Transient receptor potential (TRP) channels are cation channels associated with cancer. To date, TRPM members including TRPM2, 4, 5, 7 and 8 have also been proven to be associated with the proliferation and survival of cells. Among TRP channels, TRPM2 is expressed in many noncancerous cells, such as the brain and peripheral blood cells. Studies show that TRPM2 is associated with various types of cancers, too [19].

TRPM2 is a member of the TRP protein superfamily of ion channels that can be activated by ADP-ribose, β -NAD, TNF- α , and H_2O_2 which results in increased values of intracellular free calcium concentration ($[Ca^{2+}]_i$) [20]. TRPM2 is a non-selective cationic, Ca^{2+} -permeable pore, and contains a unique C-terminal region exhibiting ADP-ribose (ADPR) hydrolase activity. The highest expression levels of TRPM2 are observed in the cells of neuronal origin and in the myeloid lineage [21].

Data suggest that TRPM2 channels function as 'death channels', because as a matter of fact, heterologous expression of TRPM2 in human embryonic kidney cells or A172 human glioblastoma cells facilitates oxidative stress-induced cell death. Furthermore, expression of TRPM2 has been demonstrated in several tumors such as hepatocellular carcinoma, prostate cancer, lymphoma, leukemia, and lung cancer cell lines in which TRPM2 reportedly may foster cell death [22]. TRPM2 is one ion channel that can be altered to increase apoptosis in cancer cells [23].

The aim of the study was to evaluate of *PARP1*, *PARP2*, *PARP3* and *TRPM2* gene expression at mRNA level in the cells of the hematopoietic system of the bone marrow in patients with acute myeloid leukemia, bone marrow from healthy patients, peripheral blood of healthy individuals, and hematopoietic stem cells from the peripheral blood after mobilization.

Methods

The study comprised a group of 84 patients. The study group consisted of 53 patients hospitalized at the Department and Clinic of Hematooncology with Bone Marrow Transplantation, Medical University of Lublin, Poland, among them 14 patients with acute myeloid leukemia - samples of bone marrow were examined, and 39 patients in remission stage who had previously suffered from hematologic illnesses - samples of hematopoietic stem cells from the peripheral blood which underwent mobilization were tested, 10 patients of the Chair and Clinic of Traumatic Surgery and Emergency Medicine, Medical University of Lublin. The patients had normal bone marrow sampled during hip replacement surgery, and 21 healthy volunteers from whom peripheral blood was collected. The study groups were similar in terms of age and gender.

The material from patients with acute myeloid leukemia was collected at the time of diagnosis, before the treatment was initiated. The patients' mean survival was 27 months and 16 days, the shortest survival time was 14 days, the longest 84 months, and over 5-year- survival was observed in 5 out of 14 patients examined. Patient characteristics are included in the table 1.

The research was approved by the Local Bioethics Commission, Medical University of Lublin (decision No KE-0254/110/2012). The examinations were carried out with the consent of the Clinic managers, all participants signed informed consent to collect the material and conduct the examinations. The research material was collected in the years 2012-2014.

Cell isolation

Mononuclear cells were isolated from the bone marrow and peripheral blood collected on EDTA anticoagulant by density gradient centrifugation using Histopaque-1077 reagent (Sigma, USA), and PBS reagent (Biomed, Poland).

Hematopoietic stem cells were isolated from the peripheral blood on the fifth day after mobilization with granulocyte growth factor using a cell separator method. The procedure of stem cell separation was performed in the Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin [24].

RNA isolation

RNA was isolated from the samples obtained from blood and marrow mononuclears. Isolation of the total cellular mRNA was carried out by the modified method of Chomczyński and Sacchi [25] using TRI-

Reagent (Sigma, USA), isopropanol (Sigma, USA), and chloroform (Sigma, USA). The concentration and purity of the isolated RNA was tested by spectrophotometry (NanoDrop 2000c).

Reverse transcription reaction

A specific fragment of the analyzed gene was obtained by amplification using cDNA synthesized on the basis 1µg of isolated RNA using commercially available Reverse Transcriptase Kits (Applied Biosystem, USA) according to the manufacturer's recommendations. The reverse transcription reaction was carried out in a volume of 20µl, consisting of: 2µl (10xRT Buffer), 0.8µl (10xdNTPs (100mM)), 2µl (10xRT Random Primer), 1µl (RNasin 40U / µl), 1µl (Reverse transcriptase 50U / µl), 3.2µl (RNAz- and DNAz-free ultrapure water), and 10µl (1µg RNA dissolved in 10 µl ultrapure water).

The reaction was carried out in a thermal cycler (Verit Thermal Cycler, Life Technologies), initially the reaction mixture was incubated for 10 minutes at 25 °C, then for 2 hours at 37 °C, followed by 5 minutes at 95 °C. The resulting cDNA was used for real-time PCR.

qPCR reaction

The analysis of gene expression was performed by real-time PCR on StepOnePlus (Applied Biosystems) using commercially available TaqMan probes (Applied Biosystems, USA) for endogenous control gene: *GAPDH*: Hs99999905_m1; for *TRPM2* gene: Hs01066071_m1; for *PARP1* gene: Hs00242302_m1 for *PARP2* gene: Hs00193931_m1 for *PARP3* test gene: Hs00193946_m1.

The qPCR reaction was carried out in 96-well-optical plates, in the volume of 25 µl / well, consisting of 10.25 µl RNAz- and DNAz-free ultrapure water, 1.25 µl gene-specific probe, 12.5 µl TaqMan Gene Expression Master Mix (Applied Biosystems, USA), and 1 µl cDNA synthesized in the reverse transcription reaction. The qPCR reaction, after the initial 10-minute denaturation at 95°C, was carried out according to the following scheme—40 cycles: 15 seconds at 95°C, and 60 seconds at 60°C.

To determine the initial amount of cDNA for a given gene in the tested samples, CT (cycle threshold) values were determined, i.e. the number of the PCR cycle after which the fluorescence exceeded the threshold line value. The value of the threshold line (threshold) was determined in the logarithmic growth phase for all tested samples after crossing the base line - the background line, determined separately for each of the samples. To normalize the expression of test genes the CT value against glyceraldehyde 3-phosphate dehydrogenase (GAPDH) reference gene was determined for each sample. Final gene expression was determined against the sample used to calibrate the entire experiment (calibrator - control sample of the peripheral blood from healthy people without leukemia).

The level of relative gene expression was calculated from the formula $RQ = 2^{-\Delta\Delta Ct}$ [26]. Data analysis was done by Expression Suite Software 1.0.3. (Life Technologies). Detailed procedures for the cells isolation, reverse transcription and real time PCR reactions have been described in our previous work, where we showed that the studied hematopoietic stem cells of peripheral blood and healthy bone marrow cells

express high level of *BIRC5* gene expression, which confirms native nature of the tested hematopoietic stem cells [27].

Statistical analysis

Statistical analysis was done by Statistica 13 software. To examine the differences between the study groups, ANOVA Kruskal-Wallis Test and U Mann-Whitney Test were applied and the Spearman's correlation test, $p < 0.05$ was assumed statistically significant.

Results

The results found *PARP1*, *PARP2*, *PARP3*, and *TRPM2* genes were expressed in all examined cells. The highest *PARP1* gene expression was found in acute myeloid leukemia cells (AML), while the lowest *PARP1* gene expression was detected in the group of hematopoietic stem cells collected from the peripheral blood after mobilization (PBSC). A statistically significant difference in the expression of *PARP1* between AML group and PBSC was demonstrated. The analysis of *PARP2* gene expression produced similar results, the highest expression was detected in AML group, while PBSC group showed the lowest expression, the difference was statistically significant. Statistical analysis of *PARP3* gene expression in the studied groups did not show significant differences. *TRPM2* gene expression was significantly different in the study groups. The highest expression was recorded in the bone marrow cells (BM), while the lowest in the peripheral blood cells (PBMC), and acute myeloid leukemia. There were significant differences in *TRPM2* gene expression between BM and AML groups, BM and PBSC, and BM and PBMC groups (Figure 1, Table 2).

The analysis of the dependence of gene expression and survival of AML patients showed statistically significantly higher *TRPM2* expression and lower *PARP1* expression in the bone marrow cells in patients whose overall survival was longer than 5 years, compared with patients whose overall survival was shorter than 5 years (Fig. 2, Table 3.A.). In the case of *PARP2* and *PARP3* expression, no significant correlation was found with the survival of AML patients. In addition, a statistically significant strong positive correlation of survival with *TRPM2* gene expression and a statistically significant strong correlation of survival with *PARP1* gene expression was demonstrated (Table 3.B.).

Statistically significant correlations between the expression of the examined genes were demonstrated. Very strong positive correlations were found between the expression of all tested genes: *PARP1* and *PARP2*, *PARP1* and *PARP3*, *PARP1* and *TRPM2*, *PARP2* and *PARP3* and *TRPM2*, *PARP3* and *TRPM2* in the group of stem cells collected from the peripheral blood after mobilization. Also in the group of bone marrow-derived stem cells, statistically significant positive correlations were observed between the expression of all tested genes: *PARP1* and *PARP2*, *PARP1* and *PARP3*, *PARP1* and *TRPM2*, *PARP2* and *PARP3*, *PARP2* and *TRPM2*, *PARP3* and *TRPM2*. In the group of hematopoietic stem cells derived from the peripheral blood after mobilization there was a statistically significant positive correlation between *PARP1* and *PARP2* gene expression, *PARP1* and *PARP3*, and *PARP3* and *PARP2*, *PARP3* and *TRPM2*. In

acute myelogenous leukemia group, there were no statistically significant relationships between the expression of the examined genes (Table 4).

Discussion

Observed by us positive correlations between *PARP1*, *PARP2*, *PARP3*, and *TRPM2* genes expression in the group of mature mononuclear cells derived from the peripheral blood and in the group of bone marrow-derived stem cells suggest that in physiological state there is mutual positive regulation of *PARPs* and *TRPM2* genes expression. In the bone marrow cells of the patients with acute myelogenous leukemia, significant correlations were not observed between the expression of the examined genes. Our research suggests that there is a different regulation of *PARP1*, *PARP2*, *PARP3*, and *TRPM2* genes expression in acute myelogenous leukemia cells.

Interestingly, the bone marrow cells of patients with acute myelogenous leukemia show over expression of *PARP1* and *PARP2* genes and decreased *TRPM2* gene expression.

In the hematopoietic stem cells derived from the normal marrow and peripheral blood after mobilization, the opposite situation was observed, i.e. *TRPM2* gene showed increased expression while *PARP1* and *PARP2* gene expression was reduced. Our studies may suggest disrupted signaling between *TRPM2* and *PARP* genes in cancer cells. In addition, the determined correlation between reduced *TRPM2* gene expression and decreased *PARP1* gene expression and shorter overall survival time indicates the prognostic significance of the expression of these genes in AML.

Similarly, the study by Zeng et al. [20] showed that knocking down *TRPM2* increased PARP activity in prostate cancer cells through a unresolved mechanism [20]. In recent years, scientists have devoted much attention to the role of TRP channels in cancer. Among other things, it has been shown that *TRPM2* is involved in cell migration and cell death, which are the key processes of cancer cell death [28]. The results of the studies by Zeng et al. [20] showed that in non-cancerous cells, *TRPM2* proteins are mainly located at the plasma membrane where they mediate sodium and calcium influx on oxidative stimulation. Cation influxes may lead to membrane depolarization and changes in calcium homeostasis that can lead to programmed cell death. In cancer cells, the role of *TRPM2* as a plasma membrane ion channel is less important because of the internalization and nuclear localization of *TRPM2*. Numerous *TRPM2* proteins are translocated into the nucleus where they may have an important enzymatic function related to cancer cell proliferation [20].

The cited studies also confirm our analyses in which we showed that in tumor cells *TRPM2* gene expression is significantly decreased whereas *PARP1* and *PARP2* expression is significantly increased, which may indicate that *TRPM2* gene loses its function in tumor cells. In addition, we have shown that in the physiological state there is a positive relationship between *PARP1*, *PARP2*, and *TRPM2*, which is disturbed in cancer cells.

Correct regulation between the examined genes is extremely important in the context of cell functioning, and its dysregulation may block apoptotic cell death, affect the progression of the cell cycle and increase cell proliferation as well as increase the possibility of DNA repair by overexpressing PARP. On the one hand, the activity of polymerase poli(ADP-ribose) depends on the intracellular calcium concentration, on the other hand polymers of (ADP-ribose) synthesized by PARP1, PARP2 and PARP3 stimulate TRPM2 in the normal cells [20].

The researchers observed that the expression of *TRPM2* in AML subgroups is the higher the more differentiated AML cells are [21]. Klumpp et al. demonstrated that TRPM2 plays a key role in response to DNA damage in leukemic T lymphocytes. The researchers argue that irradiated Jurkat cells use TRPM2 channels to control cell cycle arrest in the G2/M phase [22]. Sumoza-Toledo et al. have demonstrated that the low *TRPM2* expression may be used to predict adverse prognosis in ER-HER + breast cancer. According to the researchers, TRPM2 is a promising biomarker of aggressiveness for breast cancer, and a potential target for new therapies [29]. TRPM2 channel has been identified as playing an important role in several types of cancers [30] including breast cancer, neuroblastoma, prostate cancer, head and neck cancer, melanoma [23], and colorectal cancer [31,32,33]. Potential TRPM2 involvement was confirmed in cell proliferation, facilitation of cell survival, prostate cancer, melanoma, genomic stability of breast cancer cells, promotion, survival and metastases in the head and neck [19]. The researchers observed that after TRPM2 silencing, the level of DNA damage in breast cancer cells was significantly increased, which was not observed in non-cancer breast cells after similar therapy [33]. So we speculate that therapy directed simultaneously at *TRPM2* and *PARPs* would cause the cancer cells death as a result of damage accumulation and the inability to DNA repair.

Many studies indicate that TRPM2 is an ion channel that is modulated, and that can be altered to increase apoptosis in cancer cells including acute leukemia cells [1]. Based on the conducted studies, we noted that the bone marrow and blood cell samples of the patients with acute leukemia showed statistically significantly lower mean *TRPM2* gene expression compared to the normal bone marrow. Reduced expression of *TRPM2* gene may be associated with disordered apoptotic cycle in cancerous cells.

Our results of *TRPM2* gene expression presented the context of survival time of AML patients showed a statistically significant correlation: the higher *TRPM2* gene expression in bone marrow cells at the time of diagnosis, the longer the mean survival time of the patients. A statistically significantly higher level of *TRPM2* gene expression was observed in the patients whose survival was longer than 5 years, compared to the patients whose survival was less than 5 years. The presented results suggest that the expression of *TRPM2* gene in the marrow cells of AML patients is a possible prognostic marker.

Our results show also increased expression of *PARP1* and *PARP2* gene in AML cells. In many studies *PARP1* expression was found to be significantly increased in several malignant tissues, e.g. breast, uterine, lung, ovarian. Within breast infiltrating ductal carcinoma samples tested, mean PARP1 expression was significantly higher compared to normal breast tissue [34].

The latest data also confirm that PARP1 was highly expressed in cytogenetically normal AML patients and AML cell lines compared to normal bone marrow cells. It may indicate that PARP1 plays a critical role in the development of AML [4]. Research by Fonfria et al. [35] confirms the hypothesis that PARP enzyme activity is a central component of the pathway linking oxidative stress with TRPM2 activation [35]. Intracellular Ca^{2+} regulation has a crucial role in tumorigenesis, including cell replication and apoptosis. Nuclear expression of *TRPM2* may also influence nuclear Ca^{2+} concentration [20].

In our studies we showed that in the bone marrow cells of patients with acute myeloid leukemia, *PARP1* and *PARP2* genes are overexpressed and *TRPM2* gene is down-regulated, which may suggest disturbed signaling between these genes. The modified TRPM2 function may suggest disturbed signaling between TRPM2 and PARPs at the transcript level, which increases the expression of polymerases. Numerous studies have reported that overexpression of *PARP* genes in turn is associated with uncontrolled cell proliferation, increased DNA repair ability, and increased telomerase activity which is associated with cell immortalization [36].

The demonstrated in our study positive correlations between *PARP1*, *PARP2*, *PARP3*, and *TRPM2* gene expression in the group of PBMC and in the group of BM cells suggest that in the physiological state there is mutual positive regulation of *PARP* family members and *TRPM2* gene expression. In the bone marrow cells from the patients with acute myelogenous leukemia, significant relationships between the expression of the test genes were not observed. Our research suggests that there is a different regulation of *PARP1*, *PARP2*, *PARP3*, and *TRPM2* gene expression in acute myelogenous leukemia cells. We speculate that correct signaling between *TRPM2* and *PARPs* is essential for physiology, and its loss may affect the development of acute leukemia. Regulation of *PARP1*, *PARP2*, *PARP3*, and *TRPM2* genes expression may provide a new therapeutic strategy against AML.

Moreover, our studies have shown that there is a negative correlation between *PARP1* gene expression and overall survival in the group of cells from the marrow of AML patients. It has been shown that the higher *PARP1* expression at the mRNA level, the shorter the patients' survival. In the group of patients whose survival was over 5 years, *PARP1* expression was statistically significantly lower in comparison with patients whose overall survival was less than 5 years, which confirms the prognostic significance of *PARP1*.

Conclusions

Our research suggests that in physiological conditions the cells of the hematopoietic system exhibit mutual positive regulation of *PARP1*, *PARP2*, *PARP3*, and *TRPM2* gene expression. In acute myelogenous leukemia cells, *PARP1*, *PARP2*, and *TRPM2* gene mRNA levels deregulate. Furthermore, survival of AML patients is associated with the expression of *PARP1* and *TRPM2* genes determined at the time of diagnosis. Therefore, there is a need for further research on the mutual regulation of *PARP1*, *PARP2*, *PARP3*, and *TRPM2* gene expression in AML.

Declarations

Ethics approval and consent to participate

The research was carried out with the approval of the Local Bioethics Commission No KE-0254/110/2012.

Consent for publication

Not applicable. This manuscript does not contain data from any individual person.

Availability of data and material

The data used to support the findings of this study are included within the article.

Competing interests

The authors declare that they have no competing interests.

Funding

This study was supported in part by funds from the project “The equipment of innovative laboratories doing research on new medicines used in the therapy of civilization and neoplastic diseases” within the Operational Program Development of Eastern Poland 2007–2013, Priority Axis I Modern Economy, Operations I.3 Innovation Promotion and in part by National Centre for Research and Development grant STRATEGMED III (STRATEGMED3/303570/7/NCBR/2017) to JK. The funder do not affect the design of the study, collection, analysis, and interpretation of data and writing the manuscript.

Authors' Contributions:

“conceptualization, P.G.-K. and J.K.; methodology, P.G.-K. and J.K. software, P.G.-K.; and W.K.; validation, M.C.; A.B.-K., M.R. and J.K.; formal analysis, P.G.-K.; investigation, P.G.-K.; E.D.; E.R.-B.; J.W.; M.F.; resources, M.F.; M.J.; A.N.; M.C.; M.R. and J.K.; data curation, P.G.-K. and J.K.; writing—original draft preparation, P.G.-K. and E.D.; writing—review and editing, P.G.-K.; E.D.; E.R.-B., J.W.; G.A.W.; M.F.; W.K.; M.J.; A.N. and J.K. visualization, P.G.-K. and E.D. supervision, M.C., A.B.-K., M.R. and J.K.; project administration, P.G.-K and J.K. funding acquisition, J.K..”

Acknowledgement

Not Applicable

Abbreviations

PBMC: peripheral blood mononuclear cells

BM: bone marrow

AML: acute myeloid leukemia

PBSC: peripheral blood stem cells

DAC: daunorubicine+cytarabine,+cladribine

CLAG: cladribine+cytarabine+G-CSF

CLAG-M: CLAG+mitoxantrone

AlloHSCT: Allogeneic stem cell transplantation

GvHD: Graft versus host disease

References

1. Yanamandra N, Buzzeo RW, Gabriel M, Hazlehurst LA, Mari Y, Beaupre DM, Cuevas J. Tipifarnib-induced apoptosis in acute myeloid leukemia and multiple myeloma cells depends on Ca²⁺ influx through plasma membrane Ca²⁺ channels. *J Pharmacol Exp Ther*. 2011;337(3):636-43. doi: 10.1124/jpet.110.172809. Epub 2011 Mar 4.
2. Wang X, Liu R, Wang Y, Cai H, Zhang L. Effects of down-regulation of clusterin by small interference RNA on human acute myeloid leukemia cells. *Int J Clin Exp Med*. 2015;8(11):20925-31. eCollection 2015.
3. Schiewer MJ, Knudsen KE. Transcriptional Roles of PARP1 in Cancer. *Mol Cancer Res*. 2014; 12(8): 1069-1080.
4. Li X, Li C, Jin J, Wang J, Huang J, Ma Z, Huang X, He X, Zhou Y, Xu Y, Yu M, Huang S, Yan X, Li F, Pan J, Wang Y, Yu Y, Jin J. High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects. *EBioMedicine*. 38:47-56. doi: 10.1016/j.ebiom.2018.11.025. Epub 2018 Nov 22. PubMed PMID: 30472087; PubMed Central PMCID: PMC6306376.
5. Ford AL, Lee JM. Climbing STAIRs towards clinical trials with a novel PARP-1 inhibitor for the treatment of ischemic stroke. *Brain Res*. 2011; 1410: 120-121.
6. Ghosh R, Roy S, Kamyab J, Danzter F, Francoa S. Common and Unique Genetic Interactions of the Poly(ADP-ribose) Polymerases PARP1 and PARP2 with DNA Double-Strand Break Repair Pathways. *DNA Repair (Amst)*. 2016; 45: 56-62.
7. Schiewer MJ, Mandigo AC, Gordon N, Huang F, Gaur S, de Leeuw R, Zhao SG, Evans J, Han S, Parsons T, Birbe R, McCue P, McNair C, Chand SN, Cendon-Florez Y, Gallagher P, McCann JJ, Poudel Neupane N, Shafi AA, Dylgjeri E, Brand LJ, Visakorpi T, Raj GV, Lallas CD, Trabulsi EJ, Gomella LG,

- Dicker AP, Kelly WK, Leiby BE, Knudsen B, Feng FY, Knudsen KE. 11 PARP-1 regulates DNA repair factor availability. *EMBO Mol Med*. 2018; 10(12): 8816.
8. Diamantopoulos P, Zervakis K, Zervakis P, Sofotasiou M, Vassilakopoulos T, Kotsianidis I, Symeonidis A, Pappa V Galanopoulos A, Solomou E, Kodandreopoulou E, Papadopoulou V, Korkolopoulou P, Mantzourani, Kyriakakis G, Viniou NA. Poly (ADP-ribose) polymerase 1 mRNA levels strongly correlate with the prognosis of myelodysplastic syndromes. *Blood Cancer J*. 2017; 7(2): 533. doi: 10.1038/bcj.2016.127.
 9. Pashaiefar H, Yaghmaie M, Tavakkoly-Bazzaz J, Ghaffari SH, Alimoghaddam K, Momeny M, Izadi P, Izadifard M, Kasaeian A, Ghavamzadeh A. PARP-1 Overexpression as an Independent Prognostic Factor in Adult Non-M3 Acute Myeloid Leukemia. *Genet Test Mol Biomarkers*. 2018; 22(6): 343-349.
 10. Li N, Wang Y, Deng W, Lin SH. Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics. *Anticancer Agents Med Chem*. 2018; 9: doi: 10.2174/1871520618666181109164645.
 11. Dudzińska E, Gryzińska M, Ognik K, Krauze M, Listos P. Non-specific inflammatory bowel disease and the risk of tumour growth. *Med.Wet*. 2018; 74(4): 228-232. DOI: 10.21521/mw.6048.
 12. Dellomo AJ, Baer MR, Rassool FV. Partnering with PARP inhibitors in acute myeloid leukemia with FLT3-ITD. *Cancer Lett*. 2019 Jul 10;454:171-178. doi: 10.1016/j.canlet.2019.03.048. Epub 2019 Apr 4.
 13. Faraoni I, Giansanti M, Voso MT, Lo-Coco F, Graziani G. Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders. *Biochem Pharmacol*. 2019 Apr 24. pii: S0006-2952(19)30154-6. doi: 10.1016/j.bcp.2019.04.019.
 14. Chiou SH, Jiang BH, Yu YL, Chou SJ, Tsai PH, Chang WC, Chen LK, Chen LH, Chien Y, Chiou GY. Poly(ADP-ribose) polymerase 1 regulates nuclear reprogramming and promotes iPSC generation without c-Myc. *J Exp Med*. 2013; 210(1): 85-98.
 15. Doege CA, Inoue K, Yamashita T, Rhee DB, Travis S, Fujita R, Guarnieri P, Bhagat G, Vanti WB, Shih A, Levine RL, Nik S, Chen EI, Abeliovich A. Early-stage epigenetic modification during somatic cell reprogramming by Parp1 and Tet2. *Nature*. 2012; 488(7413): 652-655.
 16. Farrés J, Llacuna L, Martin-Caballero J, Martinez C, Lozano JJ, Ampurdanes C, Lopez-Contreras AJ, Florensa L, Navarro J, Ottina E, Dantzer F, Schreiber V, Villunger A, Fernandez-Capetillo O, Yelamos J. PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors. *Cell Death Differ*. 2015; 22(7): 1144-1157.
 17. Jiang BH, Tseng WL, Li HY, Wang ML, Chang YL, Sung YJ, Chiou SH. Poly(ADP-Ribose) Polymerase: Cellular Pluripotency, Reprogramming, and Tumorigenesis. *Int J Mol Sci*. 2015; 16(7): 15531-15545.
 18. Roper SJ, Chrysanthou S, Senner CE, Sienerth A, Gnan S, Murray A, Masutani M, Latos P, Hemberger M. ADP-ribosyltransferases Parp1 and Parp7 safe guard pluripotency of ES cells. *Nucleic Acids Res*. 2014; 42(14): 8914-8927.
 19. Zhao L, Xu W, Xu, Z, Qi C.Y, Li Y, Cheng J., Liu L., Wu Y., Gao J., Ye J.. The overexpressed functional transient receptor potential channel TRPM2 in oral squamous cell carcinoma. *Scientific Reports* 2016 volume 6, Article number: 38471

20. Zeng X, Sikka SC, Huang L, Sun C, Xu C, Jia D, Abdel-Mageed AB, Pottle JE, Taylor JT, Li M. Novel role for the transient receptor potential channel TRPM2 in prostate cancer cell proliferation. *Prostate Cancer Prostatic Dis.* 2010;13(2):195-201.
21. Haladyna JN, Pastuer T, Riedel SS, Perraud AL, Bernt KM. Transient potential receptor melastatin-2 (Trpm2) does not influence murine MLL-AF9-driven AML leukemogenesis or in vitro response to chemotherapy. *Exp Hematol.* 2016;44(7):596-602.e3.
22. Klumpp D, Misovic M, Szteyn K, Shumilina E, Rudner J, Huber SM. Targeting TRPM2 Channels Impairs Radiation-Induced Cell Cycle Arrest and Fosters Cell Death of T Cell Leukemia Cells in a Bcl-2-Dependent Manner. *Oxidative Medicine and Cellular Longevity.* Volume 2016, Article ID 8026702, 14 pages
23. Blake SD, Tweed MC, McKamey SG, Koh DW. Transient receptor potential, Melastatin-2 (TRPM2) blockade: perspectives on potential novel clinical utility in cancer. *Translational Cancer Research* 2017, Vol 6, Supplement 2
24. Borowska, P. Klimek and M. Cioch, "The obtaining of peripheral blood stem cells and evaluation of its viability in the apheresis product before and after cryopreservation," *Journal of Laboratory Diagnostics*, 50,3, pp.249-254, 2014
25. Chomczynski P, Sacchi N. Single-Step Method of Isolation by Acid Guanidinium Thiocyanate- Phenol-Chloroform Extraction. *Anal Biochem.* 1987;162:156–9.
26. K.J. Livak and T.D. Schmittgen, "Analysis of Relative Gene Expression Data Using RealTime Quantitative PCR and the 2- $\Delta\Delta$ CT Method," *METHODS*, 25, pp.402–8, 2001.
27. Gil-Kulik P, Krzyżanowski A, Dudzińska E, Karwat J, Chomik P, Świstowska M, Kondracka A, Kwaśniewska A, Cioch M, Jojczuk J, Nogalski A, Kocki J. Potential involvement of BIRC5 in maintaining pluripotency and cell differentiation of human stem cells. *Oxidative Medicine and Cellular Longevity* [online] 2018 vol. 2018, art. ID 8727925.
28. Sumoza-Toledo A, Penner R. TRPM2: a multifunctional ion channel for calcium signalling. *J Physiol.* 2011;589(Pt 7):1515-25.
29. Sumoza-Toledo A, Espinoza-Gabriel MI, Montiel-Condado D. Evaluation of the TRPM2 channel as a biomarker in breast cancer using public databases analysis. *Bol Med Hosp Infant Mex.* 2016;73(6):397-404
30. Miller BA. TRPM2 in Cancer. *Cell Calcium.* 2019 Mar 6;80:8-17. doi: 10.1016/j.ceca.2019.03.002.
31. Ibrahim S, Dakik H, Vandier C, Chautard R, Paintaud G, Mazurier F, Lecomte T, Guéguinou M, Raoul W. Expression Profiling of Calcium Channels and Calcium-Activated Potassium Channels in Colorectal Cancer. *Cancers (Basel).* 2019 Apr 19;11(4). pii: E561.
32. Dudzińska E, Gryzinska M, Ognik K, Gil-Kulik P, Kocki J, Oxidative Stress and Effect of Treatment on the Oxidation Product Decomposition Processes in IBD, *Oxidative Medicine and Cellular Longevity*, vol. 2018, Article ID 7918261, 7 pages, 2018. <https://doi.org/10.1155/2018/7918261>.
33. Hopkins MM, Feng X, Liu M, Parker LP, Koh DW. Inhibition of the transient receptor potential melastatin-2 channel causes increased DNA damage and decreased proliferation in breast

adenocarcinoma cells. *Int J Oncol.* 2015;46(5):2267-76.

34. Ossovskaya V, Koo IC, Kaldjian EP, Alvares C, Sherman BM. Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types. *Genes Cancer.* 2010;1(8):812–821. doi:10.1177/1947601910383418
35. Fonfria E, Marshall IC, Benham CD, Boyfield I, Brown JD, Hill K, Hughes JP, Skaper SD, McNulty S. TRPM2 channel opening in response to oxidative stress is dependent on activation of poly(ADP-ribose) polymerase. *Br J Pharmacol.* 2004 Sep;143(1):186-92. doi: 10.1038/sj.bjp.0705914. Epub 2004 Aug 9. PubMed PMID: 15302683; PubMed Central PMCID: PMC1575275.
36. Ngo G, Hyatt S, Grimstead J, Jones R, Hendrickson E, Pepper C, Baird D. PARP inhibition prevents escape from a telomere-driven crisis and inhibits cell immortalisation. *Oncotarget.* 2018 Dec 25;9(101):37549-37563. doi: 10.18632/oncotarget.26499. eCollection 2018 Dec 25.

Tables

Table 1. Characteristics of patients with acute myeloid leukemia

Sex	Age	Karyotype abnormalities	Therapy	Cause of death
F	68	+8	DAC	Sepsis after induction therapy
F	19	Normal	DAC, consolidation, AlloHSCT	GvHD, infection complications
F	57	Unknown	DAC	Sepsis after induction therapy
M	60	Unknown	CLAG	Refractoriness on therapy
F	62	Inv(16)	DAC, consolidation	Alive
M	56	Complex changes	CLAG	Refractoriness on therapy
M	43	Normal	DAC, consolidation	Relapse
M	30	t(8;21)	DAC, consolidation	Alive
M	54	-Y	DAC, consolidation	Aspergillosis
F	48	Complex changes	DAC, CLAG-M, consolidation, AlloHSCT	Relapse
M	55	Normal	DAC, consolidation, AlloHSCT	Relapse
F	35	Complex changes	DAC, consolidation, AlloHSCT	Relapse
M	34	Normal	DAC, CLAG-M	Refractoriness on therapy, aspergillosis
F	48	Normal	DAC, Consolidation, AlloHSCT	Relapse

Table 2. Mean *PARP1*, *PARP2*, *PARP3*, and *TRPM2* gene expression ($2^{-\Delta\Delta C_t} \pm SE$) in tested groups

* ANOVA Kruskal-Wallis Test

Mean gene expression in tested group								
Gene	Group	N	Mean $2^{-\Delta\Delta C_T}$	SE	<i>p</i> -value			
					AML	PBMC	PBSC	BM
<i>PARP1</i>	AML	14	3.572	1.099		0.156	0.001*	0.455
	PBMC	21	1.185	0.146	0.156	0.968	0.899	
	PBSC	39	0.615	0.054	0.001*	0.968	0.379	
	BM	10	1.243	0.121	0.455	0.899	0.379	
<i>PARP2</i>	AML	14	7.463	2.709		0.163	0.003*	0.224
	PBMC	21	0.923	0.110	0.163	0.992	0.988	
	PBSC	39	0.709	0.086	0.003*	0.992	0.799	
	BM	10	1.349	0.271	0.224	0.988	0.799	
<i>PARP3</i>	AML	14	1.684	0.394		0.858	0.700	0.973
	PBMC	21	0.888	0.101	0.858	1.000	0.989	
	PBSC	39	0.808	0.083	0.700	1.000	0.990	
	BM	10	0.984	0.126	0.973	0.989	0.990	
<i>TRPM2</i>	AML	14	4.191	2.317		0.997	0.841	0.016*
	PBMC	21	0.549	0.178	0.997	0.828	0.025*	
	PBSC	39	1.934	0.612	0.841	0.828	0.033*	
	BM	10	10.392	2.039	0.016*	0.025*	0.033*	

Table 3. A. Mean *PARP1*, *PARP2*, *PARP3*, and *TRPM2* gene expression ($2^{-\Delta\Delta C_T} \pm SE$) in groups depending on survival time (<5 years, >5 years), * U Mann Withney Test. **B.** Correlation of *PARP1*, *PARP2*, *PARP3* and *TRPM2* gene expression with survival time *p<0.05, Spearman's correlation test.

A. Mean gene expression in tested group depending on survival time					B. Correlations between gene expression and survival time	
Gene	Survival time [years]	Mean $2^{-\Delta\Delta C_T}$	SE	p-value	survival time	
<i>PARP1</i>	< 5	4.201	1.254	0.049*	-0.732*	
	> 5	0.737	0.161			
<i>PARP2</i>	< 5	8.799	3.160	0.422	-0.033	
	> 5	1.453	0.312			
<i>PARP3</i>	< 5	1.594	0.446	0.559	0.141	
	> 5	1.983	1.002			
<i>TRPM2</i>	< 5	0.803	0.393	0.013*	0.633*	
	> 5	21.134	16.354			

Table 4. Correlation of *PARP1*, *PARP2*, *PARP3*, and *TRPM2* gene expression in tested group, *p<0.05, Spearman's correlation test

Correlation of *PARP1*, *PARP2*, *PARP3* and *TRPM2* gene expression in tested group

Gene	Group	<i>RQ PARP1</i>	<i>RQ PARP2</i>	<i>RQ PARP3</i>	<i>RQ TRPM2</i>
<i>RQ PARP1</i>	AML	0.489	0.541	-0.564	
<i>RQ PARP2</i>		0.489	0.301	-0.075	
<i>RQ PARP3</i>		0.541	0.301	-0.201	
<i>RQ TRPM2</i>		-0.564	-0.075	-0.201	
<i>RQ PARP1</i>	PBMC	0.965*	0.950*	0.890*	
<i>RQ PARP2</i>		0.965*	0.991*	0.911*	
<i>RQ PARP3</i>		0.950*	0.991*	0.951*	
<i>RQ TRPM2</i>		0.890*	0.911*	0.951*	
<i>RQ PARP1</i>	PBSC	0.778*	0.693*	0.284	
<i>RQ PARP2</i>		0.778*	0.820*	0.236	
<i>RQ PARP3</i>		0.693*	0.820*	0.398*	
<i>RQ TRPM2</i>		0.284	0.236	0.398*	
<i>RQ PARP1</i>	BM	0.929*	0.964*	0.607*	
<i>RQ PARP2</i>		0.929*	0.821*	0.571*	
<i>RQ PARP3</i>		0.964*	0.821*	0.536*	
<i>RQ TRPM2</i>		0.607*	0.571*	0.536*	

Figures

Figure 1

Mean *PARP1*, *PARP2*, *PARP3* and *TRPM2* gene expression ($2^{-\Delta\Delta C_t} \pm SE$) in groups of cells from the peripheral blood of healthy patients (PBMC), bone marrow of healthy patients (BM), bone marrow cells of

acute myeloid leukemia (AML) patients and the peripheral blood stem cells after mobilization (PBSC),
*p<0.05

Figure 2

Mean PARP1, PARP2, PARP, and TRPM2 gene expression (2-ΔΔCt ± SE) in cell groups of bone marrow of acute myeloid leukemia (AML) patients depending on survival time (> 5 years, < 5 years) *p<0.05